Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The APL Channel

Explore the latest updates and expert interviews

Welcome to The Acute Promyelocytic Leukemia (APL) Channel

VJHemOnc covers exciting and topical research directly from the experts at major international congresses so that you can stay informed.

Many patients with acute promyelocytic leukemia are cured with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). However, ongoing research is looking into improving the early identification and treatment of patients, developing strategies for high-risk patients, and examining maintenance therapies in low-risk patients. For more information, watch our video interviews with leading experts.

The challenges of predicting and diagnosing differentiation syndrome 2:24
The challenges of predicting and diagnosing differentiation syndrome
Stéphane de Botton • 19 Sep 2026
Differentiation syndrome: lessons from ATRA in APL and current diagnostic criteria 6:10
Differentiation syndrome: lessons from ATRA in APL and current diagnostic criteria
Ghayas Issa • 18 Sep 2026
Differentiation syndrome in APL: parallels with IDH and menin inhibitors in AML 9:36
Differentiation syndrome in APL: parallels with IDH and menin inhibitors in AML
Stéphane de Botton • 18 Sep 2026
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps 6:18
Differentiation syndrome in menin inhibitor-treated patients: recognition, management & next steps
Eunice Wang et al. • 18 Sep 2026
Will MRD eradication become a routine treatment goal in AML? 1:09
Will MRD eradication become a routine treatment goal in AML?
Farhad Ravandi • 21 Sep 2026
Health-related QoL in patients with high-risk APL treated with arsenic trioxide: APOLLO trial 1:03
Health-related QoL in patients with high-risk APL treated with arsenic trioxide: APOLLO trial
Fabio Efficace • 13 Jun 2026
Updated ELN recommendations for MRD monitoring in AML: key insights and takeaways 2:00
Updated ELN recommendations for MRD monitoring in AML: key insights and takeaways
Maria Teresa Voso • 12 Jun 2026
Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia 4:17
Final analysis of the APOLLO trial: ATRA-ATO versus AIDA in high-risk acute promyelocytic leukemia
Maria Teresa Voso • 12 Jun 2026
Long-term outcomes of patients with APL treated with ATO plus ATRA in the GIMEMA APL0406 study 1:30
Long-term outcomes of patients with APL treated with ATO plus ATRA in the GIMEMA APL0406 study
Alfonso Piciocchi • 24 Jun 2025
The biggest challenges in managing APL: differentiation syndrome and early deaths 2:36
The biggest challenges in managing APL: differentiation syndrome and early deaths
Maria Teresa Voso • 17 Mar 2025
Novel approaches in APL: combining oral arsenic with ATRA 1:42
Novel approaches in APL: combining oral arsenic with ATRA
Maria Teresa Voso • 17 Mar 2025
Guidance for treating APL in the frontline and R/R settings 3:14
Guidance for treating APL in the frontline and R/R settings
Maria Teresa Voso • 17 Mar 2025
A novel approach: targeting MYC for the treatment of acute leukemias 4:39
A novel approach: targeting MYC for the treatment of acute leukemias
Michael Andreeff • 18 Mar 2025
A pooled analysis of baseline health-related QoL in patients with AML, APL, and MDS 2:41
A pooled analysis of baseline health-related QoL in patients with AML, APL, and MDS
Fabio Efficace • 6 Dec 2024
APOLLO: ATO-ATRA versus standard ATRA + chemotherapy for patients with newly diagnosed high-risk APL 4:05
APOLLO: ATO-ATRA versus standard ATRA + chemotherapy for patients with newly diagnosed high-risk APL
Uwe Platzbecker • 14 Jun 2024
First results of the APOLLO trial: ATRA-ATO versus SoC in high-risk acute promyelocytic leukemia 1:42
First results of the APOLLO trial: ATRA-ATO versus SoC in high-risk acute promyelocytic leukemia
Uwe Platzbecker • 25 Jun 2024

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals